Dr. Abdulelah Alhawsawi, is the CEO of Novo
Genomics. Novo Genomic’s Vision is to be:
regionally trusted, globally recognized
biotechleader in the field of genomics & multiomics.
Dr. Alhawsawi the Former - founding Director
General of the Saudi Patient Safety Center
(SPSC), and MOH Advisor on Patient Safety.
Heled the efforts to establishing SPSC as a
WHO Collaborating Center for patient safety
policies and strategies (1 of only 5 WHOcc
worldwide in this field). He holds Dual
Certified Boards (American - Canadian) of
general surgery with sub-specialty in
Transplant and Hepatobiliary Surgery.
He is a consultant to several national and
international quality and safety organizations
and recently became a board member and
Vice President of the Global Sepsis Alliance
(GSA) as well as a Board member of Joint
Commission Resources Board. He was part of
the Expert Panel on the 3rd Global Patient
Safety Challenge of the WHO and chaired the
Organizing Committee for the 4th Global
Ministerial Summit on Patient Safety in
Jeddah, Saudi Arabia in 2019.
Dr. Alhawsawi has helped introduce Patient
Safety as a G20 priority in the 2020 G20 of
Saudi Arabia.Currently, Dr. Alhawsawi is part
of the WHO’s Global Patient Safety Action Plan
Taskforce.
